Update: ODYSSEY Outcomes
Update on ODYSSEY Outcomes – by Dr. Rajesh Dave, MD, FSCAI, FACC ODYSSEY Outcomes, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor, this time in an acute
Update on ODYSSEY Outcomes – by Dr. Rajesh Dave, MD, FSCAI, FACC ODYSSEY Outcomes, the second of the cardiovascular outcomes studies with a PCSK9 inhibitor, this time in an acute